APP and Alzheimer disease: It has been reported that treatment with Pioglitazone normalized the altered CRMP2 phosphorylation level, p35 protein level, impaired motor coordination ability and long-term depression (LTD) at the pre-Aβ accumulation stage in APP/PS1 mice model of AD [77].